Pirsidomine

Pirsidomine is a nitric oxide donor. Pirsidomine is a sydnonimine compound. Pirsidomine can transform into a nitric oxide-releasing metabolite in vivo. Pirsidomine prevents occlusion-induced increase in flow in the non-occluded circumflex coronary artery and significantly reduces the blood flow in non-ischemic areas in myocardial infarction dog model. Pirsidomine can be studied in research on cardiovascular diseases[1][2].

Product Specifications

CAS Number

[132722-74-8]

UNSPSC

12352005

Target

Endogenous Metabolite

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

C[C@H]1N([N+]2=NOC([N-]C(C3=CC=C(OC)C=C3)=O)=C2)[C@H](CCC1)C

Molecular Formula

C17H22N4O3

Molecular Weight

330.38

References & Citations

[1]Martorana, P. A., et al., (1994) . Antiischemic effects of pirsidomine, a new nitric oxide donor. European journal of pharmacology, 257 (3), 267-273. |[2]Stengele, E., et al., (1996) . Short-term hemodynamic, anti-ischemic, and antianginal effects of pirsidomine, a new sydnonimine. The American journal of cardiology, 77 (11), 937-941.